AR057202A1 - Derivados de pirimidina para el tratamiento de crecimiento celular anormal - Google Patents

Derivados de pirimidina para el tratamiento de crecimiento celular anormal

Info

Publication number
AR057202A1
AR057202A1 ARP060105269A ARP060105269A AR057202A1 AR 057202 A1 AR057202 A1 AR 057202A1 AR P060105269 A ARP060105269 A AR P060105269A AR P060105269 A ARP060105269 A AR P060105269A AR 057202 A1 AR057202 A1 AR 057202A1
Authority
AR
Argentina
Prior art keywords
treatment
cellular growth
abnormal cellular
pirimidine derivatives
solvates
Prior art date
Application number
ARP060105269A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR057202A1 publication Critical patent/AR057202A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a sales, solvatos y solvatos subestequiométricos de N-[3-[[[2-[(2,3-dihidro-2-oxo-1H-indol-5-il)amino]-5-(trifluorometil)-4-pirimidinil]amino]metil]-2-piridinil]-N-metilmetanosulfonamida. La presente también proporciona composiciones farmacéuticas que comprenden tales complejos, así como procedimientos para tratar crecimiento celular anormal administrando los complejos de la presente.
ARP060105269A 2005-12-01 2006-11-29 Derivados de pirimidina para el tratamiento de crecimiento celular anormal AR057202A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74125205P 2005-12-01 2005-12-01

Publications (1)

Publication Number Publication Date
AR057202A1 true AR057202A1 (es) 2007-11-21

Family

ID=38092618

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105269A AR057202A1 (es) 2005-12-01 2006-11-29 Derivados de pirimidina para el tratamiento de crecimiento celular anormal

Country Status (7)

Country Link
US (1) US8722884B2 (es)
EP (1) EP1966192B1 (es)
JP (2) JP5134234B2 (es)
AR (1) AR057202A1 (es)
CA (1) CA2632149C (es)
TW (1) TWI374880B (es)
WO (1) WO2007063384A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA97834C2 (ru) 2007-04-18 2012-03-26 Пфайзер Продактс Инк. Производные сульфониламида для лечения анормального роста клеток
MX2010014057A (es) * 2008-06-17 2011-03-21 Astrazeneca Ab Compuestos de piridina.
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
CA2827171C (en) 2011-02-17 2019-04-09 Cancer Therapeutics Crc Pty Limited Fak inhibitors
CA2827172C (en) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5924990B2 (ja) * 1979-11-21 1984-06-13 協和醗酵工業株式会社 新規なピペリジン誘導体
GB9222700D0 (en) * 1992-10-29 1992-12-09 Smithkline Beecham Plc Chemical compounds
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
BR9810866B1 (pt) * 1997-07-29 2010-07-13 composição farmacêutica em uma forma de formulação auto-emulsificante para compostos lipofìlicos.
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
JP2001261654A (ja) * 2000-03-21 2001-09-26 Mitsui Chemicals Inc キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬
JP2005512984A (ja) * 2001-11-02 2005-05-12 シャイアー バイオケム インコーポレイテッド ジオキソランヌクレオシド類似体を含む白血病の治療のための医薬組成物
EP1625121B1 (en) * 2002-12-20 2010-02-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) * 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06013164A (es) * 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
JP2007537238A (ja) * 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療のためのピリミジン誘導体
CA2566477A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
JP5134234B2 (ja) 2013-01-30
CA2632149A1 (en) 2007-06-07
US20110033441A1 (en) 2011-02-10
WO2007063384A2 (en) 2007-06-07
EP1966192A2 (en) 2008-09-10
JP2007153892A (ja) 2007-06-21
US8722884B2 (en) 2014-05-13
WO2007063384A3 (en) 2007-10-04
CA2632149C (en) 2011-11-15
EP1966192B1 (en) 2012-10-17
TW200730507A (en) 2007-08-16
TWI374880B (en) 2012-10-21
JP2012255038A (ja) 2012-12-27

Similar Documents

Publication Publication Date Title
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
AR057202A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
ECSP10010419A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
CL2008002255A1 (es) Compuesto 3-({4-(2,2-difluoroetil)-3-(1h-pirrolo [2,3-b] piridin-5-il)-1h-pirazol-4-il] pirimidin-2-il}amino)propanonitrilo, inhibidor de raf; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del crecimiento celular anormal o cualquier enfermedad o afeccion mediada por raf.
CO6612267A2 (es) Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden
ECSP10010654A (es) Derivados de tienopiridonas como activadores de proteína quinasa activados por amp (ampk)
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
MX2010009922A (es) Activadores de piridazinona glucocinasa.
CO6300954A2 (es) Derivados de tienopiridinonas como activadores de proteina quinasa activados por ampk
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
MX2010006893A (es) Derivados de benzotiazol y benzoxazol y metodos de uso.
NO20082445L (no) Neuropeptid-2 reseptor-agonister
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
CR11482A (es) Derivados de 1,2,3-triazol para uso como inhibidores de estearoil-coenzima a desaturasa
NI200700313A (es) Aminopirimidinas como moduladores de la cinasa .
NO20082096L (no) Azaindol-2-karboksamidderivativer
NI200700316A (es) Aminopirimidinas como moduladores de la cinasa
MX2010002191A (es) Composiciones y metodos que emplean antagonistas nmda para lograr un efecto anestesico limitado.
NO20081905L (no) Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander
ECSP10010664A (es) Derivados de urea heterocíclicos para el tratamiento de infecciones bacterianas
ECSP10010659A (es) Derivados heterocíclicos de la urea y sus métodos de empleo
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
WO2008104473A3 (en) Pyrazolopyriidine derivatives and their use as kinase inhibitors

Legal Events

Date Code Title Description
FB Suspension of granting procedure